ENOXAPARIN LEDRAXEN 4,000 I.U (40 mg)/ 0.4 ml Price

Overview

Welcome to Dwaey, specifically on ENOXAPARIN LEDRAXEN 4,000 I.U (40 mg)/ 0.4 ml Solution for injection page.
This medicine contains an important and useful components, as it consists of Enoxaparin sodium.
ENOXAPARIN LEDRAXEN 4,000 I.U (40 mg)/ 0.4 ml is available in the market in concentration 4,000 I.U (40 mg)/0.4 ml and in the form of Solution for injection .

VENIPHARM GMBH is the producer of ENOXAPARIN LEDRAXEN 4,000 I.U (40 mg)/ 0.4 ml and it is imported from GERMANY, The most popular alternatives of ENOXAPARIN LEDRAXEN 4,000 I.U (40 mg)/ 0.4 ml are listed downward .

Mode Of Action

Enoxaparin is a low molecular weight heparin w/ anticoagulant properties. It acts by enhancing the inhibition rate of activated clotting factors including thrombin and factor Xa through its action on antithrombin III.

Indication

• Myocardial infarction
• Unstable angina
• Venous thromboembolism
• Deep vein thrombosis

Precaution

Renal or hepatic impairment, history of GI ulceration, uncontrolled hypertension, spinal or epidural anaesthesia; lactation and pregnancy; elderly. Periodic blood counts, platelet count and stool occult blood test recommended. Lactation: Excretion in milk unknown; not recommended

Side Effects

• 1-10% Hemorrhage (1-4%)
• Elevation of serum aminotransferases (6%)
• Fever (5-8%)
• Local site reactions (2-5%)
• Thrombocytopenia (3%)
• Nausea (3%)
• Anemia (2%)
• Ecchymosis (3%) <1% Atrial fibrillation
• Heart failure
• Pulmonary edema
• Pneumonia Potentially Fatal: Haemorrhagic complications.

Contra indication

Hypersensitivity, acute bacterial endocarditis; major bleeding disorder, haemorrhagic stroke, drug-induced thrombocytopenia.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.